2011

Drs. Lockery and Weeks founded NemaMetrix

University of Oregon Professor Shawn Lockery applied microfluidics techniques, which involve precise control and manipulation of constrained fluids to move the worms around in a predictable manner. Dr. Lockery realized that this new technique could be used as a precise and cost-effective drug screening tool. Collaborating with fellow University of Oregon Professor Janis Weeks, who had a background in electrophysiology and neural circuits, Shawn was able to turn his microfluidics concept into a functional prototype for use in rapidly screening drug candidates. This work was funded by a two-year NIH grant to the Lockery lab.

2014

ScreenChip platform technology was recognized by the White House as one of the breakthrough life science research technologies.

NemaMetrix was one of the five finalists who received the award under the Obama Administration. The ScreenChip System was considered a disruptive high-throughput, low cost, and easy-to-use platform for drug development based on physiological monitoring of the model organism Caenorhabditis elegans.

2017

NemaMetrix and Knudra Transgenics merge to add CRISPR genome editing capabilities.

NemaMetrix adds the capability of creating custom transgenics by joining forces with Knudra Transgenics, a pioneer and an expert in providing transgenic C. elegans and zebrafish based in Salt Lake City. The combined company is in a stronger position to provide expertise and solutions to answer genome-to-phenome questions.

2017

NemaMetrix becomes the winner of the first "Most Innovative" health startup selected by CB Insights.

While more than 2,000 companies applied for the opportunity to pitch at Demo Day, NemaMetrix was one of 40 companies chosen to present at the A-ha! Conference. CB Insights selected NemaMetrix as part of an elite group of startups driving progress in artificial intelligence, fintech, health and bleeding-edge technologies.

2018

NemaMetrix expands its genome editing expertise into creation of genetically modified zebrafish.

The company adds the capability of creating genetic models using zebrafish for understanding gene function, basic biology, and more precisely modeling human diseases.

2019

NemaMetrix launches its first end-to-end in vivo analytical service to produce data and insights for early-stages of drug development.

NemaMetrix`s in vivo analytical services produce data and insights for companies that need to make go/no-go decisions quickly and help researchers understand the mechanism of action, analyze gene function, and advance the development of compounds and therapies.

2020

NemaMetrix changes its operating name to InVivo Biosystems to capitalize on its in-vivo analysis platform.

The company expands its research platforms to help researchers develop and deliver therapeutic solutions for critical diseases. The company’s in-vivo analyses provide essential services to pharmaceutical, nutraceuticals, and biotechnology companies around the world to accelerate research and drug development efforts, enabling earlier insights by closing the gap between cells and mice.

2020

InVivo Biosystems adds COVID-19 environmental testing via partnership and aids research efforts in drug and vaccine development.

The company starts to offer environmental and lab testing for the detection of the COVID-19 virus from surface and air samples through a partnership with a local startup, Enviral Tech, Inc. In addition, the company`s genetic engineering expertise enables the creation humanized genetic models for COVID-19 research.

2021

InVivo Biosystems enters the nutraceutical space

InVivo Biosystems enters nutraceutical space leveraging its Longevity Platform and provides nutraceutical firms with data analysis on the effect of healthy-aging ingredients and formulations (evidence-based claims).

C. elegans Extrachromosomal Array Service